Write in a clean editor, then format for European Urology Open Science in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
European Urology Open Science is a peer-reviewed journal published by Elsevier, covering Prostate Cancer Diagnosis and Treatment, Bladder and Urothelial Cancer Treatments, Prostate Cancer Treatment and Research.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, European Urology Open Science 12 (2023) 45–58.
Formats any DOI in European Urology Open Science style. No sign-up. |
| Publishes research in | Prostate Cancer Diagnosis and Treatment Bladder and Urothelial Cancer Treatments Prostate Cancer Treatment and Research Renal cell carcinoma treatment Urological Disorders and Treatments |
| ISSN | 2666-1683 |
| Citation impact (2-yr) | 0.6 |
| h-index | 37 |
| i10-index | 316 |
| Total citations | 10,184 |
| Article processing charge | $1,800 |
| Open access | Yes |
| Top institutions publishing here | University College London |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: Urolithiasis is among the most common urologic diagnoses globally, with substantial burden and cost on healthcare systems worldwide. Increasing evidence links urolithiasis with an array of risk factors, including diet and lifestyle trends, noncommunicable diseases such as diabetes and obesity, and global warming. OBJECTIVE: To examine geographic, temporal, and sociodemographic patterns to better understand…
A phase 1b study of photosensitizer TLD-1433–mediated photodynamic therapy (PDT) was performed in bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) patients. The primary objectives were safety and tolerability of PDT, with secondary objectives of (1) pharmacokinetic (PK) properties of TLD-1433 and (2) efficacy, as evaluated by recurrence-free survival and complete response (CR) at 90 and…
Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on real-world usage and outcomes are limited. To examine real-world treatment patterns and clinical outcomes for mRCC. This retrospective cohort study included 1538 patients with mRCC who received first-line treatment with pembrolizumab + axitinib (P…
It has been hypothesized that M2 macrophages and regulatory T cells (Tregs) may contribute to tumor progression by suppression of antitumor immunity. To investigate the association between infiltration of CD163+ M2 macrophages and CD4+FOXP3+ Tregs with clinical outcomes in renal cell carcinoma patients. A cohort of 346 patients diagnosed with renal cell carcinoma at Örebro…
Existing tumor markers for testicular germ cell tumor (TGCT) cannot detect the presence of pure teratoma. Serum miRNAs have strong performance detecting other subtypes of TGCT. Previous reports suggest high levels of miR-375 expression in teratoma tissue. The purpose of this study was to explore the role of serum miRNA, including miR-375, in detecting the…
